NO328470B1 - Vektor for a uttrykke en sekvens i en tumorcelle og vertcelle omfattende denne, samt fremgangsmater for a uttrykke sekvensen in vitro og anvendelse av vektoren for fremstilling av et medikament for behandling av cancer. - Google Patents

Vektor for a uttrykke en sekvens i en tumorcelle og vertcelle omfattende denne, samt fremgangsmater for a uttrykke sekvensen in vitro og anvendelse av vektoren for fremstilling av et medikament for behandling av cancer. Download PDF

Info

Publication number
NO328470B1
NO328470B1 NO20001684A NO20001684A NO328470B1 NO 328470 B1 NO328470 B1 NO 328470B1 NO 20001684 A NO20001684 A NO 20001684A NO 20001684 A NO20001684 A NO 20001684A NO 328470 B1 NO328470 B1 NO 328470B1
Authority
NO
Norway
Prior art keywords
sequence
gene
vector
expression
promoter
Prior art date
Application number
NO20001684A
Other languages
English (en)
Norwegian (no)
Other versions
NO20001684D0 (no
NO20001684L (no
Inventor
Abraham Hochberg
Suhail Ayesh
Original Assignee
Yissum Res Dev Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yissum Res Dev Co filed Critical Yissum Res Dev Co
Publication of NO20001684D0 publication Critical patent/NO20001684D0/no
Publication of NO20001684L publication Critical patent/NO20001684L/no
Publication of NO328470B1 publication Critical patent/NO328470B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/65—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Diabetes (AREA)
  • Toxicology (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Plant Pathology (AREA)
  • Endocrinology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
NO20001684A 1997-10-03 2000-03-31 Vektor for a uttrykke en sekvens i en tumorcelle og vertcelle omfattende denne, samt fremgangsmater for a uttrykke sekvensen in vitro og anvendelse av vektoren for fremstilling av et medikament for behandling av cancer. NO328470B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US94360897A 1997-10-03 1997-10-03
PCT/IL1998/000486 WO1999018195A2 (en) 1997-10-03 1998-10-04 Methods and compositions for inducing tumor-specific cytotoxicity

Publications (3)

Publication Number Publication Date
NO20001684D0 NO20001684D0 (no) 2000-03-31
NO20001684L NO20001684L (no) 2000-06-02
NO328470B1 true NO328470B1 (no) 2010-02-22

Family

ID=25479934

Family Applications (2)

Application Number Title Priority Date Filing Date
NO20001684A NO328470B1 (no) 1997-10-03 2000-03-31 Vektor for a uttrykke en sekvens i en tumorcelle og vertcelle omfattende denne, samt fremgangsmater for a uttrykke sekvensen in vitro og anvendelse av vektoren for fremstilling av et medikament for behandling av cancer.
NO20093194A NO331723B1 (no) 1997-10-03 2009-10-22 Vektor som kan utrykke et cytotoksisk genprodukt samt anvendelse av en slik vektor for fremstilling av et preparat for behandling av kreft

Family Applications After (1)

Application Number Title Priority Date Filing Date
NO20093194A NO331723B1 (no) 1997-10-03 2009-10-22 Vektor som kan utrykke et cytotoksisk genprodukt samt anvendelse av en slik vektor for fremstilling av et preparat for behandling av kreft

Country Status (17)

Country Link
US (2) US6087164A (cs)
EP (1) EP1019499B1 (cs)
JP (3) JP5153031B2 (cs)
KR (1) KR100524262B1 (cs)
CN (1) CN1229496C (cs)
AT (1) ATE407948T1 (cs)
AU (1) AU755774B2 (cs)
BR (1) BR9812717B1 (cs)
CA (1) CA2308124C (cs)
CZ (2) CZ294941B6 (cs)
DE (1) DE69840001D1 (cs)
HU (1) HU228470B1 (cs)
IL (1) IL135430A0 (cs)
NO (2) NO328470B1 (cs)
PL (1) PL339949A1 (cs)
RU (1) RU2214280C2 (cs)
WO (1) WO1999018195A2 (cs)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040006220A1 (en) * 2002-07-02 2004-01-08 Isis Pharmaceuticals Inc. Antisense modulation of insulin-like growth factor 2 expression
US7041654B2 (en) 1997-10-03 2006-05-09 Yissum Research Development Company Of The Hebrew University Of Jerusalem Methods and compositions for inducing tumor-specific cytotoxicity
DE19956568A1 (de) 1999-01-30 2000-08-17 Roland Kreutzer Verfahren und Medikament zur Hemmung der Expression eines vorgegebenen Gens
CA2365901A1 (en) * 1999-04-14 2000-10-19 Musc Foundation For Research Development Tissue-specific and pathogen-specific toxic agents and ribozymes
DE19928342A1 (de) * 1999-06-21 2000-12-28 Deutsches Krebsforsch Vektoren zur gentherapeutischen Tumorbehandlung
US7829693B2 (en) * 1999-11-24 2010-11-09 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of a target gene
US20040209263A1 (en) * 2000-12-07 2004-10-21 Clawson Gary A. Selection of catalytic nucleic acids targeted to infectious agents
US8546143B2 (en) 2001-01-09 2013-10-01 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of a target gene
US20040005567A1 (en) * 2002-07-02 2004-01-08 Isis Pharmaceuticals Inc. Antisense modulation of cyclin-dependent kinase 4 expression
JPWO2003102186A1 (ja) * 2002-05-31 2005-09-29 株式会社メディネット 癌細胞特異的発現誘導ｄｎａ、および癌細胞特異的発現ベクター
US20040180844A1 (en) * 2003-03-10 2004-09-16 Fesik Stephen W. Method of killing cancer cells
US20040220085A1 (en) * 2003-05-02 2004-11-04 Jasbir Sandhu Compositions for nucleic acid delivery
US20040219099A1 (en) * 2003-05-02 2004-11-04 Jasbir Sandhu Method for the treatment of tumors
US7482156B2 (en) * 2003-10-15 2009-01-27 Cell Genesys, Inc. Hepatocellular carcinoma specific promoter and uses thereof
US7063947B2 (en) * 2004-04-08 2006-06-20 Promogen, Inc. System for producing synthetic promoters
US7429482B2 (en) * 2005-01-13 2008-09-30 United States Of America As Represented By The Department Of Veterans Affairs Screening tools for discovery of novel anabolic agents
ES2435774T3 (es) 2005-07-07 2013-12-23 Yissum Research Development Company, Of The Hebrew University Of Jerusalem Agentes de ácido nucleico para la regulación negativa de H19, y métodos de uso del mismo
WO2007034487A1 (en) 2005-09-22 2007-03-29 Yissum Research Development Company Of The Hebrew University Of Jerusalem Nucleic acid constructs, pharmaceutical compositions and methods of using same for treating cancer
WO2008087641A2 (en) * 2007-01-16 2008-07-24 Yissum Research Development Company Of The Hebrew University Of Jerusalem H19 silencing nucleic acid agents for treating rheumatoid arthritis
MX2010003371A (es) 2007-09-28 2010-05-05 Intrexon Corp Constructos interruptores genicos terapeuticos y biorreactores para la expresion de moleculas bioterapeuticas y usos de los mismos.
EP2203187B1 (en) * 2007-10-25 2012-08-29 Yissum Research Development Company of the Hebrew University of Jerusalem, Ltd. Constructs containing multiple expression cassettes for cancer therapy
JP5388138B2 (ja) 2008-07-02 2014-01-15 株式会社大塚製薬工場 人工腎臓前駆体およびその製造方法
WO2010084488A1 (en) 2009-01-20 2010-07-29 Ramot At Tel-Aviv University Ltd. Mir-21 promoter driven targeted cancer therapy
EA016223B1 (ru) * 2009-10-07 2012-03-30 Учреждение Российской Академии Наук Институт Молекулярной Генетики Ран Способ и генная конструкция для высокоспецифичного ингибирования нежелательного роста клеток
SG11201708760PA (en) * 2015-05-05 2017-11-29 Yissum Res Dev Co Of Hebrew Univ Jerusalem Ltd Nucleic acid-cationic polymer compositions and methods of making and using the same
BR112020021962A2 (pt) * 2018-04-30 2021-01-26 Amicus Therapeutics, Inc. construtos para terapia gênica e métodos de uso
CN110714075B (zh) * 2018-07-13 2024-05-03 立森印迹诊断技术（无锡）有限公司 一种用于检测肺肿瘤良恶性程度的分级模型及其应用
CN111206093A (zh) * 2018-11-21 2020-05-29 立森印迹诊断技术（无锡）有限公司 一种用于检测浸润性膀胱癌的标志物及其应用
CN109609505A (zh) * 2019-01-14 2019-04-12 中国科学院成都生物研究所 一种体内筛选的剪切rna的锤头状核酶

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2576303B1 (fr) * 1985-01-21 1987-04-10 Derivan Sa Procede d'obtention de squalene et de squalane a partir de sous-produits du raffinage des huiles vegetales
FR2699191B1 (fr) * 1992-12-16 1995-02-10 Univ Paris Curie Nouveaux vecteurs rétroviraux, lignées cellulaires les contenant, et leur utilisation dans le traitement des tumeurs.
US5631236A (en) * 1993-08-26 1997-05-20 Baylor College Of Medicine Gene therapy for solid tumors, using a DNA sequence encoding HSV-Tk or VZV-Tk
IL108879A (en) * 1994-03-07 2000-08-31 Yissum Res Dev Co Diagnostic assay for malignancies using the H19 gene and kit
FR2723697B1 (fr) * 1994-08-17 1996-09-20 Rhone Poulenc Rorer Sa Methode de traitement de la restenose par la therapie genique
FR2725213B1 (fr) * 1994-10-04 1996-11-08 Rhone Poulenc Rorer Sa Vecteurs viraux et utilisation en therapie genique

Also Published As

Publication number Publication date
BR9812717B1 (pt) 2011-06-28
HU228470B1 (en) 2013-03-28
IL135430A0 (en) 2001-05-20
NO20001684D0 (no) 2000-03-31
NO20001684L (no) 2000-06-02
WO1999018195A2 (en) 1999-04-15
CN1229496C (zh) 2005-11-30
ATE407948T1 (de) 2008-09-15
NO331723B1 (no) 2012-03-05
JP5153031B2 (ja) 2013-02-27
KR100524262B1 (ko) 2005-10-28
CN1280616A (zh) 2001-01-17
CA2308124A1 (en) 1999-04-15
CZ20001201A3 (cs) 2000-09-13
KR20010030912A (ko) 2001-04-16
EP1019499B1 (en) 2008-09-10
CZ294941B6 (cs) 2005-04-13
US6087164A (en) 2000-07-11
AU9457198A (en) 1999-04-27
US6306833B1 (en) 2001-10-23
NO20093194L (no) 2000-06-02
BR9812717A (pt) 2000-08-22
EP1019499A2 (en) 2000-07-19
HUP0003745A3 (en) 2002-04-29
RU2214280C2 (ru) 2003-10-20
CA2308124C (en) 2008-07-08
JP2001519148A (ja) 2001-10-23
JP2008136480A (ja) 2008-06-19
PL339949A1 (en) 2001-01-15
DE69840001D1 (de) 2008-10-23
AU755774B2 (en) 2002-12-19
CZ294694B6 (cs) 2005-02-16
WO1999018195A3 (en) 1999-08-12
JP2006304801A (ja) 2006-11-09
HUP0003745A2 (hu) 2001-02-28

Similar Documents

Publication Publication Date Title
NO331723B1 (no) Vektor som kan utrykke et cytotoksisk genprodukt samt anvendelse av en slik vektor for fremstilling av et preparat for behandling av kreft
JP2025028917A (ja) 核酸構築物及び使用方法
CN113874512A (zh) 诱导毛细胞分化的组合物和方法
WO2022167009A1 (zh) 靶向Aqp1 mRNA的sgRNA及其载体与应用
CN113557010A (zh) 用于递送治疗剂的腺相关病毒载体
US7041654B2 (en) Methods and compositions for inducing tumor-specific cytotoxicity
JP2001520875A (ja) 血管新生の刺激のための遺伝子治療
JP4528446B2 (ja) 前立腺特異的膜抗原遺伝子のイントロン３を含む調節構築物
CN114729021B (zh) 能破坏细胞的氨基酸序列及相关核苷酸序列和相关的应用
Qin et al. The 3′-end of the human β-actin gene enhances activity of the β-actin expression vector system: construction of improved vectors
WO1999050411A2 (en) Tumour-specific expression control region and the use thereof
IL135430A (en) Use of a polynucleotide capable of expressing a cytotoxic gene product in the production of a pharmaceutical composition for treating tumors
MXPA00003251A (en) Methods and compositions for inducing tumor-specific cytotoxicity
KR102957630B1 (ko) 핵산 구조체 및 사용 방법
JP2003529321A (ja) Ｐ−ｈｙｄｅファミリーの単離された核酸、ｐ−ｈｙｄｅタンパク質、及び癌における細胞死の誘導に対する感受性を誘導する方法
CN117836420A (zh) 重组tert编码病毒基因组和运载体
HK40109651A (zh) 重组tert编码病毒基因组和运载体
CN114854791A (zh) 一种新型CRISPR-Cas9系统载体及其应用
AU2002343189A1 (en) Methods and compositions for inducing tumor-specific cytotoxicity

Legal Events

Date Code Title Description
MK1K Patent expired